STRO — Sutro Biopharma Share Price
0.000.00%
Last trade - 00:00- $92.80m
- -$224.10m
- $62.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.08 | ||
| Price to Tang. Book | 2.08 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -93.4% | ||
| Return on Equity | -234.19% | ||
| Operating Margin | -384.34% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 42.72 | 61.88 | 67.77 | 153.73 | 62.04 | 47.15 | 47.75 | 7.74% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
Directors
- Connie Matsui NEC (67)
- William Newell CEO (63)
- Edward Albini CFO (63)
- Linda Fitzpatrick CHO (64)
- Robert Kiss SVP
- Trevor Hallam CSO (62)
- David Pauling GCN
- Shabbir Anik OTH (68)
- Jane Chung OTH
- Arturo Molina OTH (62)
- Heidi Hunter DRC
- James Panek DRC (68)
- Daniel Petree DRC (65)
- Michael Dybbs IND (46)
- John Freund IND (67)
- Joseph Lobacki IND (62)
- Shalini Sharp IND (44)
- Jon Wigginton IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 21st, 2003
- Public Since
- September 27th, 2018
- No. of Shareholders
- 63
- No. of Employees
- 310
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 84,363,322
- Address
- 111 Oyster Point Blvd., SOUTH SAN FRANCISCO, 94080
- Web
- https://www.sutrobio.com/
- Phone
- +1 6503928412
- Contact
- Emily White
- Auditors
- Ernst & Young LLP
Upcoming Events for STRO
Sutro Biopharma Inc at Bank of America Global Healthcare Conference
Q1 2025 Sutro Biopharma Inc Earnings Release
Sutro Biopharma Inc Annual Shareholders Meeting
Sutro Biopharma Inc Annual Shareholders Meeting
Q2 2025 Sutro Biopharma Inc Earnings Release
Similar to STRO
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Sutro Biopharma share price?
As of Today at 23:31 UTC, shares in Sutro Biopharma are trading at $1.10. This share price information is delayed by 15 minutes.
How has the Sutro Biopharma share price performed this year?
Shares in Sutro Biopharma last closed at $1.10 and the price had moved by -72.08% over the past 365 days. In terms of relative price strength the Sutro Biopharma share price has underperformed the S&P500 Index by -74.83% over the past year.
What are the analyst and broker recommendations for Sutro Biopharma?
The overall consensus recommendation for Sutro Biopharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sutro Biopharma dividend yield?
Sutro Biopharma does not currently pay a dividend.
Does Sutro Biopharma pay a dividend?
Sutro Biopharma does not currently pay a dividend.
When does Sutro Biopharma next pay dividends?
Sutro Biopharma does not currently pay a dividend.
How do I buy Sutro Biopharma shares?
To buy shares in Sutro Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sutro Biopharma?
As of the previous close price of $1.10, shares in Sutro Biopharma had a market capitalisation of $92.80m.
Where are Sutro Biopharma shares listed?
Here are the trading details for Sutro Biopharma:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: STRO
What kind of share is Sutro Biopharma?
Based on an overall assessment of its quality, value and momentum Sutro Biopharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sutro Biopharma share price forecast for 2025?
The analyst consensus target price for shares in Sutro Biopharma is $4.25. That is 286.36% above the last closing price of $1.10.
Analysts covering Sutro Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$2.20 for the next financial year.
Find out moreWhat is the trend in the Sutro Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sutro Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -68.87%.
As of the last closing price of $1.10, shares in Sutro Biopharma were trading -57.66% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sutro Biopharma PE Ratio?
The Sutro Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sutro Biopharma?
Sutro Biopharma's management team is headed by:
- Connie Matsui - NEC
- William Newell - CEO
- Edward Albini - CFO
- Linda Fitzpatrick - CHO
- Robert Kiss - SVP
- Trevor Hallam - CSO
- David Pauling - GCN
- Shabbir Anik - OTH
- Jane Chung - OTH
- Arturo Molina - OTH
- Heidi Hunter - DRC
- James Panek - DRC
- Daniel Petree - DRC
- Michael Dybbs - IND
- John Freund - IND
- Joseph Lobacki - IND
- Shalini Sharp - IND
- Jon Wigginton - IND